Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
C16008 trial (ixazomib): what clinicians have said so far
Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma
- NCT01383928 ↗
- Completed
- Millennium Pharmaceuticals, Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on C16008 (ixazomib plus lenalidomide plus dexamethasone in newly diagnosed multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on C16008 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 YouTube videos, typically up to 13 once built | |
| 1 post on X, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of IXAZOMIB (MLN9708), Administered Twice-weekly in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Multiple Myeloma
- Interventions
- Ixazomib; Lenalidomide; Dexamethasone
- Arms
- Phase 1: Ixazomib 3 mg or 3.7 mg · Experimental
- Phase 2: Ixazomib 3 mg · Experimental
- Enrollment
- 64
- Primary outcomes
- Phase 1: Maximum Tolerated Dose (MTD)
- Phase 1: Recommended Phase 2 Dose (RP2D)
- Phase 1: Percentage of Participants Experiencing 1 or More Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)
- Phase 1: Number of Participants With Markedly Abnormal Laboratory Values Reported as Treatment Emergent Adverse Events (TEAEs)
- Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAE) Related to Neurotoxicity
- Phase 1: Number of Participants With Clinically Significant Change From Baseline in Vital Signs
- Phase 2: Percentage of Participants With Complete Response (CR) + Very Good Partial Response (VGPR)
- Phase 2: Percentage of Participants With Grade 3 or Higher Adverse Events
- Phase 2: Percentage of Participants Experiencing Serious Adverse Events
- Phase 2: Percentage of Participants With Treatment-Emergent Adverse Events Resulting in Study Drug Discontinuation
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Start
- Oct 31, 2011
- Primary completion
- Oct 13, 2014
- Results posted
- Yes
- Registry record
- NCT01383928 · updated Mar 21, 2019